Market Overview :
The global digital pathology market is projected to reach USD 1,139 million by 2025 from USD 613 million in 2020, at a CAGR of 13.2% during the forecast period. The growth of this market is majorly attributed to the increasing adoption of digital pathology to enhance lab efficiency, rising prevalence of cancer, and the growing application of digital pathology in drug development & companion diagnostics. However, a lack of trained pathologists is expected to challenge market growth in the coming years.
Recent Developments :
In 2019, Leica Biosystems (US) launched the Aperio GT 450
In 2019, F. Hoffmann-La Roche Ltd (Switzerland) launched the uPath enterprise software
In 2019, XIFIN (US) launched VisualStrata
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844
Geographic Analysis :
North America accounted for the largest share of the digital pathology market in 2019. The large share of this region in the global digital pathology market can be attributed to the increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives by the government in the US and Canada. The North American market is also expected to grow at the highest rate during the forecast period.
Key Market Players :
The major players in the global digital pathology market are Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan). Other prominent players in this market include Roche (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (India), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD (China), Inspirata, Inc. (US), Mikroscan Technologies (US), Proscia Inc. (US), Kanteron Systems (Spain).
The global digital pathology market is projected to reach USD 1,139 million by 2025 from USD 613 million in 2020, at a CAGR of 13.2% during the forecast period. The growth of this market is majorly attributed to the increasing adoption of digital pathology to enhance lab efficiency, rising prevalence of cancer, and the growing application of digital pathology in drug development & companion diagnostics. However, a lack of trained pathologists is expected to challenge market growth in the coming years.
Recent Developments :
In 2019, Leica Biosystems (US) launched the Aperio GT 450
In 2019, F. Hoffmann-La Roche Ltd (Switzerland) launched the uPath enterprise software
In 2019, XIFIN (US) launched VisualStrata
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844
Geographic Analysis :
North America accounted for the largest share of the digital pathology market in 2019. The large share of this region in the global digital pathology market can be attributed to the increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives by the government in the US and Canada. The North American market is also expected to grow at the highest rate during the forecast period.
Key Market Players :
The major players in the global digital pathology market are Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan). Other prominent players in this market include Roche (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (India), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD (China), Inspirata, Inc. (US), Mikroscan Technologies (US), Proscia Inc. (US), Kanteron Systems (Spain).
Comments
Post a Comment